Surface Oncology to present non clinical data for SRF388, SRF114

Surface Oncology announced the presentation of two posters at the 2022 Society for Immunotherapy of Cancer, SITC, Annual Meeting in Boston. The posters feature new non-clinical data for both SRF388 and for SRF114 and will be presented on Friday, November 11, 2022. "We are very pleased to share intriguing new non-clinical data that suggest there is immune-suppressive cross-talk between IL-27 and PD-L1 expression within the tumor microenvironment," said Vito Palombella, PhD, Chief Scientific Officer, Surface Oncology. "Immunohistochemical analysis of IL-27, the IL-27 receptor, and PD-L1 shows co-localization across several cancer types, and in vitro studies have shown that IL-27 can directly upregulate PD-L1 expression on both immune and tumor cells. These data support our ongoing clinical studies evaluating SRF388, our first-in-class, fully human anti-IL-27 antibody, in combination with pembrolizumab." SITC Poster Presentations: Title: IL-27 expressed in the tumor microenvironment is correlated with PD-L1 levels and can induce PD-L1 expression on immune and tumor cells. Summary of key data: Primary tumor samples from several cancers including lung, liver, renal, gastric, and head and neck, have IL-27+ tumor associated macrophages; IL-27-expressing TAMs are localized within the vicinity of PD-L1+ tumor cells in lung and liver cancers, with the highest IL-27+ density being associated with the highest PD-L1 expression; IL-27 can regulate PD-L1 expression in immune cells and tumor cell lines. Title: SRF114, an afucosylated anti-CCR8 antibody, depletes intratumoral Treg cells and reduces tumor growth. Summary of key data: CCR8 expression is highest on intratumoral regulatory T cells compared to peripheral Tregs and other immune cells; SRF114 treatment results in dose-dependent activation of immune cells, including natural killer cells and monocytes; In dissociated tumor cultures, SRF114 selectively depletes Treg cells and has limited impact on effector T cells; in a mouse model, SRF114 treatment significantly reduces tumor growth and depletes intratumoral Treg cells, with minimal impact on peripheral Tregs.